A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: Validation and comparison with previous models

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 913-921

  Koo, Dong Hoe ^a   Ryoo, Baek Yeol ^a   Kim, Hwa Jung ^a   Ryu, Min Hee ^a   Lee, Sung Sook ^a,b   Moon, Jung Hwa ^a   Chang, Heung Moon ^a   Lee, Jae Lyun ^a   Kim, Tae Won ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Prognosis; Stomach neoplasms; Tumor burden; Validation studies

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; FLUOROPYRIMIDINE; HEMOGLOBIN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARDIA; CREATININE BLOOD LEVEL; EASTERN EUROPE COOPERATIVE ONCOLOGY GROUP PERFORMANCE SCORE; FEMALE; GASTRECTOMY; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MODEL; OVERALL SURVIVAL; PERITONEUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TUMOR LOCALIZATION; VALIDATION STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REGISTRIES; RISK FACTORS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 80054732938     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1561-8     Document Type: Article

References (36)

1. P Hohenberger S Gretschel 2003 Gastic cancer Lancet 362 9380 305 315 10.1016/s0140-6736(03)13975-x 12892963 10.1016/S0140-6736(03)13975-X (Pubitemid 36936845)
2. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (3):CD004064
3. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 1 37 41 8508427 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P 1:STN:280:DyaK3s3osVGqtQ%3D%3D (Pubitemid 23182046)
4. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 3 587 591 7533517 10.1038/bjc.1995.114 1:STN:280:DyaK2M7os1ertg%3D%3D
5. B Glimelius K Ekström K Hoffman W Graf P-O Sjödén U Haglund C Svensson L-K Enander T Linné H Sellsröm R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 2 163 168 9093725 10.1023/A:1008243606668 1:STN:280:DyaK2s3kslGqug%3D%3D (Pubitemid 27112884)
6. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon G Middleton F Daniel J Oates AR Norman 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 1 36 46 10.1056/NEJMoa073149 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
7. Y-K Kang W-K Kang D-B Shin J Chen J Xiong J Wang M Lichinitser Z Guan R Khasanov L Zheng M Philco-Salas T Suarez J Santamaria G Forster PI McCloud 2009 Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 4 666 673 10.1093/annonc/mdn717 19153121 10.1093/annonc/ mdn717
8. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi M-L Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study group J Clin Oncol 24 31 4991 4997 10.1200/jco.2006.06.8429 17075117 10.1200/JCO.2006.06.8429 (Pubitemid 46631401)
9. SS Lee J-L Lee M-H Ryu HM Chang TW Kim H-J Kang WK Kim JS Lee Y-K Kang 2007 Combination chemotherapy with capecitabine (x) and cisplatin (p) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis Jpn J Clin Oncol 37 1 30 37 17272321 10.1093/jjco/hyl134 (Pubitemid 47096440)
10. S Sym H Chang M-H Ryu J-L Lee T Kim J Yook S Oh B Kim Y-K Kang 2010 Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer Ann Surg Oncol 17 4 1024 1032 19941081 10.1245/s10434-009-0838-1
11. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 12 2395 2403 10.1200/Jco.2004.08. 154 15197201 10.1200/JCO.2004.08.154 (Pubitemid 41121931)
12. J Lee T Lim JE Uhm KW Park SH Park SC Lee JO Park YS Park HY Lim TS Sohn JH Noh JS Heo CK Park S Kim WK Kang 2007 Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 18 5 886 891 10.1093/annonc/mdl501 17298958 10.1093/annonc/mdl501 1:STN:280:DC%2BD2s3ns1Klsg%3D%3D (Pubitemid 47054086)
13. JG Kim BY Ryoo YH Park BS Kim TY Kim YH Im YK Kang 2008 Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy Cancer Chemoth Pharm 61 2 301 307 10.1007/s00280-007-0476-x 10.1007/s00280-007-0476-x 1:CAS:528:DC%2BD2sXhtlWrs77E (Pubitemid 350160328)
14. Y Yagi A Seshimo S Kameoka 2000 Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses Gastric Cancer 3 2 71 80 11984714 10.1007/PL00011699 (Pubitemid 32182879)
15. M Yoshida A Ohtsu N Boku Y Miyata K Shirao Y Shimada I Hyodo W Koizumi M Kurihara S Yoshida S Yamamoto 2004 Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the japan clinical oncology group (JCOG) study Jpn J Clin Oncol 34 11 654 659 15613554 10.1093/jjco/hyh120 (Pubitemid 41615277)
16. V Catalano F Graziano D Santini S D'Emidio AM Baldelli D Rossi B Vincenzi P Giordani P Alessandroni E Testa G Tonini G Catalano 2008 Second-line chemotherapy for patients with advanced gastric cancer: who may benefit [quest] Br J Cancer 99 9 1402 1407 18971936 10.1038/sj.bjc.6604732 1:CAS:528: DC%2BD1cXhtlSktb%2FF
17. I Chau S Ashley D Cunningham 2009 Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study J Clin Oncol 27 19 e3 e4 10.1200/jco.2009.22. 0863 19470917 10.1200/JCO.2009.22.0863
18. A Gallo C Cha 2006 Updates on esophageal and gastric cancers World J Gastroenterol 12 20 3237 3242 16718845 (Pubitemid 43881349)
19. MA Eloubeidi R Desmond MR Arguedas CE Reed CM Wilcox 2002 Prognostic factors for the survival of patients with esophageal carcinoma in the US Cancer 95 7 1434 1443 12237911 10.1002/cncr.10868
20. WW Rosser 1999 Application of evidence from randomised controlled trials to general practice Lancet 353 9153 661 664 10.1016/s0140-6736(98)09103-x 10030347 10.1016/S0140-6736(98)09103-X 1:STN:280:DyaK1M7ltlCiug%3D%3D (Pubitemid 29087995)
21. A Schattner RH Fletcher 2003 Research evidence and the individual patient QJM 96 1 1 5 12509644 10.1093/qjmed/hcg001 1:STN:280:DC%2BD3s%2FgtlOgsQ%3D%3D (Pubitemid 36163806)
22. BC Cho HC Jeung HJ Choi SY Rha WJ Hyung JH Cheong SH Noh HC Chung 2007 Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute J Surg Oncol 95 6 461 468 10.1002/jso.20731 17192913 10.1002/jso.20731 (Pubitemid 46709389)
23. Y Kanemitsu H Kondo H Katai H Nakayama H Asamura R Tsuchiya T Naruke 1998 Surgical resection of pulmonary metastases from gastric cancer J Surg Oncol 69 3 147 150 9846500 10.1002/(SICI)1096-9098(199811)69:3<147::AID-JSO5>3.0. CO;2-H 1:STN:280:DyaK1M%2FmtV2gtg%3D%3D (Pubitemid 28549889)
24. JB Dupont Jr JR Lee GR Burton I Cohn Jr 1978 Adenocarcinoma of the stomach: review of 1,497 cases Cancer 41 3 941 947 638980 10.1002/1097- 0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M (Pubitemid 8313231)
25. HS Kim SY Yi HJ Jun J Lee JO Park YS Park J Jang HJ Kim Y Ko HY Lim WK Kang 2007 Clinical outcome of gastric cancer patients with bone marrow metastases Oncology 73 3-4 192 197 18418012 10.1159/000127386 (Pubitemid 351630049)
26. Y Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki, S Park, H Lim, J Wu, B Langer, Shah MA (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28 (7 suppl):abstr LBA4007
27. J Kim C-L Sun B Mailey C Prendergast A Artinyan S Bhatia A Pigazzi JDI Ellenhorn 2010 Race and ethnicity correlate with survival in patients with gastric adenocarcinoma Ann Oncol 21 1 152 160 10.1093/annonc/mdp290 19622590 10.1093/annonc/mdp290 1:STN:280:DC%2BD1Mfisl2ntg%3D%3D
28. A-M Bouvier M Sant A Verdecchia D Forman R Damhuis J Willem Coebergh E Crocetti P Crosignani L Gafa G Launoy C Martinez-Garcia I Plesko V Pompe-Kirn J Rachtan M Velten M Vercelli M Zwierko J Esteve J Faivre 2010 What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 46 6 1086 1092 10.1016/j.ejca.2010.01.019 20163952 10.1016/j.ejca.2010. 01.019
29. SAD Byfield CC Earle JZ Ayanian EP McCarthy 2009 Treatment and outcomes of gastric cancer among United States-born and foreign-born Asians and Pacific Islanders Cancer 115 19 4595 4605 19626648 10.1002/cncr.24487
30. C Li S Kim JF Lai WJ Hyung WH Choi SH Choi SH Noh 2007 Advanced gastric carcinoma with signet ring cell histology Oncology 72 1-2 64 68 18004078 10.1159/000111096 (Pubitemid 350249131)
31. J-M Park Y-J Jang J-H Kim S-S Park S-H Park S-J Kim Y-J Mok C-S Kim 2008 Gastric cancer histology: clinicopathologic characteristics and prognostic value J Surg Oncol 98 7 520 525 10.1002/jso.21150 18802956 10.1002/jso.21150
32. S Gill A Shah N Le EF Cook EM Yoshida 2003 Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center J Clin Oncol 21 11 2070 2076 10.1200/jco.2003.11.054 12775731 10.1200/JCO.2003.11.054 (Pubitemid 46606354)
33. Y Jiang 2009 Advanced gastric cancer: a disease of diverse clinical biology Gastrointest Cancer Res 3 3 125 126 19626158
34. Anne-Marie B, Milena S, Arduino V, David F, Ronald D, Jan Willem C, Emanuele C, Paolo C, Lorenzo G, Guy L, Carmen M-G, Ivan P, Vera P-K, Jadwiga R, Michel V, Marina V, Maria Z, Jacques E, Jean F (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? European journal of cancer (Oxford, England: 1990) 46(6):1086-1092
35. A Ohtsu S Yoshida N Saijo 2006 Disparities in gastric cancer chemotherapy between the east and west J Clin Oncol 24 14 2188 2196 10.1200/jco.2006.05.9758 16682738 10.1200/JCO.2006.05.9758 (Pubitemid 46630691)
36. Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA (2010) A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. doi: 10.1093/annonc/mdq032